January 4, 2023 Our portfolio company, Immunis, announced the first-in-human injection of its stem cell secretome product to treat age and disease-related immune decline
December 27, 2022 Nanoparticles to treat aging and age-related diseases – interview with Louis Hawthornes
December 23, 2022 The NIH awards the SenNet Consortium $190M to support senescent cell research. The capital comes from a $660M strategic fund reserved for projects with the potential to transform biomedical research.
November 25, 2022 Targeting the immune system to extend healthspan – interview with Dr. Hans Keirstead
January 4, 2023 Our portfolio company, Immunis, announced the first-in-human injection of its stem cell secretome product to treat age and disease-related immune decline
December 27, 2022 Nanoparticles to treat aging and age-related diseases – interview with Louis Hawthornes
December 23, 2022 The NIH awards the SenNet Consortium $190M to support senescent cell research. The capital comes from a $660M strategic fund reserved for projects with the potential to transform biomedical research.
November 25, 2022 Targeting the immune system to extend healthspan – interview with Dr. Hans Keirstead